Claims
- 1. A method for detecting SLE antibodies in serum, comprising:
- (a) contacting serum, for a period of time at least sufficient to permit equilibration of binding between SLE antibodies and cardiolipin, with liposomes having a multicomponent liposome bilayer comprising a flexible double tailed phosphatidylcholine and cardiolipin in a molar ratio of from about 1:7 to about 7:1, respectively;
- (b) exposing said liposomes to conditions which cause destablization of the liposomes in the absence of SLE antibodies and which do not cause destablization of the liposomes in the presence SLE antibodies; and
- (c) detecting any destablization of the liposomes,
- said method being performed under conditions non-inhibiting to the binding between SLE antibodies and said cardiolipin.
- 2. The method according to claim 1, wherein said ratio is from about 2:5 to about 4:3.
- 3. The method according to claim 1, wherein said liposomes contain entrapped therein a divalent cation responsive colorimetric indicator, and said conditions causing destablization comprise contacting said liposomes with divalent cations which results in leakage and a change in color of the indicator.
- 4. The method according to claim 3, wherein the divalent cations are magnesium or calcium cations.
- 5. A method for detecting SLE antibodies in serum, comprising:
- (a) contacting serum, for a period time sufficient to permit equilibration of binding between SLE antibodies and a phosphatidic acid antigen which binds to SLE antibodies, with liposomes having a multicomponent liposome bilayer comprising a flexible double tailed phosphatidylcholine and said phosphatidic acid antigen in molar ratios of from about 9:1 to about 3:7, respectively, said liposomes being unstable in the presence of calcium ions unless SLE antibodies are present;
- (b) exposing said liposomes to calcium ions; and
- (c) detecting any destabilization of the liposomes,
- said method being performed under conditions non-inhibiting to the binding between SLE antibodies and said phosphatidic acid antigen.
- 6. The method according to claim 5, wherein said phosphatidic acid is dipalmitoylphosphatidic acid, and said liposomes have a multicomponent liposome bilayer comprising egg phosphatidylcholine, dipalmitoylphosphatidic acid, cholesterol and dicetylphosphate in molar ratios of about 7:1:1:1, respectively.
- 7. The method according to claim 5, wherein said liposomes contain entrapped therein a divalent cation responsive colorimetric indicator, and said destablization results in an influx of divalent cations into the liposomes which results in a change in color of the indicator.
- 8. A method for detecting SLE antibodies in serum, comprising:
- (a) contacting serum, for a period of time at least sufficient to permit equilibration of binding between SLE antibodies and a phosphatidic acid antigen which binds to SLE antibodies, with liposomes having a multicomponent liposome bilayer comprising a flexible double tailed phosphatidylcholine and said phosphatidic acid antigen in a molar ratio of from about 1:7 to about 7:1, respectively, said liposomes being stable in the presence of serum containing SLE antibodies and unstable in the presence of serum not containing SLE antibodies; and
- (b) detecting any liposome instability, said method being performed under conditions non-inhibiting to the binding between SLE antibodies and said phosphatidic acid antigen.
- 9. The method according to claim 8, wherein said ratio is from about 2:5 to about 4:3.
- 10. The method according to claim 8, wherein said phosphatidic acid is 1-palmitoyl-2-oleoylphosphatidic acid.
- 11. The method according to claim 8, wherein said liposomes contain entrapped therein a colorimetric indicator, and said instability is detected by a color change in said indicator which is released from the liposomes in the absence of SLE antibodies.
- 12. The method according to claim 11, wherein said indicator is responsive to divalent metal ions and is exposed to divalent cations upon release from the liposomes.
- 13. The method according to claim 12, wherein the divalent metal ions are magnesium ions.
- 14. The method according to claim 1, 5 or 8, wherein the anionic lipid components of the bilayer are cesium or potassium salts.
- 15. The method according to claim 1, 5 or 8, wherein said phosphatidylcholine is 1-palmitoyl-2-oleoylphosphatidylcholine.
- 16. The method according to claim 1, 5 or 8, wherein said liposome bilayer contains a stabilizing amount of a rigid steriod stabilizer.
- 17. The method according to claim 16, wherein said steroid is cholesterol.
- 18. The method according to claim 17, wherein the stabilizing amount is from about 5 to about 30 molar percent, relative to the total amount of said phosphatidylcholine and phosphatidic acid or cardiolipin.
- 19. The method according to claim 1 or 8, wherein said liposome bilayer contains from about 10 to about 20 molar percent, relative to the total amount of said phosphatidylcholine and phosphatidic acid or cardiolipin, of a liposome compatible negatively charged compound.
- 20. The method according to claim 19, wherein said liposome compatible negatively charged compound is phosphatidylglycerol.
- 21. The method according to claim 20, wherein said phosphatidylglycerol is dipalmitoyl-phosphatidyl glycerol.
- 22. The method according to claim 5, wherein said liposome bilayer contains from about 10 to about 20 molar percent, relative to the total amount of phosphatidylcholine and phosphatidic acid, of dicetylphosphate.
- 23. The method according to claim 1, 5 or 8, wherein said liposome bilayer contains a stabilizing amount of an antioxidant.
- 24. The method according to claim 23, wherein said antioxidant is alpha-tocopherol in an amount corresponding to from about 1 to about 5 molar percent of the total amount of said phosphatidylcholine and phosphatidic acid or cardiolipin.
- 25. The method according to claim 1, wherein said bilayer comprises 1-palmitoyl-2-oleoylphosphatidylcholine, cardiolipin, cholesterol, alpha-tocopherol and dipalmitoyl phosphatidylglycerol in a molar ratio of about 3:4:1.9:0.1:1, respectively.
- 26. The method according to claim 8, wherein said bilayer comprises 1-palmitoyl-2-oleoylphosphatidylcholine, 1-palmitoyl-2-oleoyl-phosphatidic acid, cholesterol, alpha-tocopherol and dipalmitoyl phosphatidylglycerol in a molar ratio of about 3:4:1.9:0.1:1, respectively.
- 27. The method according to claim 1, 5 or 8, wherein said indicator is arsenazo III.
- 28. A liposome composition comprising liposome vesicles, said vesicles having (i) a multicomponent liposome bilayer comprising a flexible double tailed phosphatidylcholine and a lipid antigen for SLE antibodies in a molar ratio of from about 1:7 to about 9:1, respectively, and (ii) a colorimetric indicator entrapped within said liposome.
- 29. A composition according to claim 28, wherein said indicator is a divalent cation responsive colorimetric indicator.
- 30. A composition according to claim 28, wherein said ratio is from about 2:5 to about 4:3.
- 31. A composition according to claim 28, wherein said lipid antigen is a phosphatidic acid or cardiolipin.
- 32. A composition according to claim 28, wherein said phosphatidylcholine is 1-palimitoyl-2-oleoylphosphatidylcholine.
- 33. A composition of claim 28, wherein said vesicles have a multicomponent liposome bilayer comprising egg phosphatidylcholine, dipalmitoylphosphatidic acid, cholesterol and dicetylphosphate in molar ratios of about 7:1:1:1, respectively.
- 34. A composition according to claim 28, wherein said liposome bilayer contains a stabilizing amount of a rigid steroid stabilizer.
- 35. A composition according to claim 34, wherein said steriod is cholesterol.
- 36. A composition according to claim 34, wherein the stabilizing amount is from about 5 to about 30 molar percent, relative to the total of amount of said phosphatidylcholine and said lipid antigen.
- 37. A composition according to claim 28, wherein said liposome bilayer contains from about 10 to about 20 molar percent, relative to the total of said phosphatidylcholine and said lipid antigen, of a liposome compatible negatively charged compound.
- 38. A composition according to claim 37, wherein said liposome compatible negatively charged compound is a phosphatidylglycerol.
- 39. A composition according to claim 38, wherein said phosphatidylglycerol is dipalmitoyphosphatidylgylycerol.
- 40. A composition according to claim 28, wherein said liposome bilayer contains a stabilizing amount of an antioxidant.
- 41. A composition according to claim 40, wherein said antioxidant is alpha-tocopherol in an amount corresponding to from about 1 to about 5 molar percent of the total amount of said phosphatidylcholine and said lipid antigen.
- 42. A composition according to claim 28, wherein said liposome bilayer comprises 1-palmitoyl-2-oleoylphosphatidylcholine, cardiolipin, cholesterol, alpha-tocopherol and dipalmitoyl phosphatidylglycerol in a molar ratio of about 3:4:1.9:0.1:1, respectively.
- 43. A composition according to claim 28, wherein said liposome bilayer comprises 1-palmitoyl-2-oleoylphosphatidylcholine, 1-palmitoyl-2-oleoyl-phosphatidic acid, cholesterol, alpha-tocopherol and dipalmitoylphosphatidylglycerol in a molar ratio of about 3:4:1.9:0.1:1, respectively.
- 44. A composition according to claim 28 or 42, wherein said indicator is arsenazo III.
- 45. A composition according to claim 28, wherein said lipid antigen is a cesium or potassium salt.
- 46. A composition according to claim 28, wherein said lipid antigen is the cesium salt of cardiolipin and wherein said liposome bilayer further comprises the potassium salt of dipalmitoylphosphatidylgycerol.
Parent Case Info
The present application is a continuation-in-part application of application Ser. No. 410,249, filed Aug. 23, 1982, and a continuation-in-part application of application Ser. No. 362,382, filed Mar. 26, 1982, both of which are incorporated herein by reference.
US Referenced Citations (3)
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO8000026 |
Jan 1980 |
WOX |
Non-Patent Literature Citations (3)
Entry |
Schieren, H. et al., Biochem. and Biophys. Res. Comm., 82 (4), pp. 1160-1167, (1978). |
Weissmann, G. et al., J. Clin. Inves., 53, pp. 536-543, (Feb. 1974). |
Weissmann, G. et al., Proc. Natl. Acad. Sci., U.S.A., 73 (2), pp. 510-514, (Feb. 1976). |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
410249 |
Aug 1982 |
|